JNJ

224.45

+1.24%↑

UNH

385.5

+1.52%↑

TMO

458.32

+0.23%↑

ISRG

427.6

-0.15%↓

ABT

83.46

+0.3%↑

JNJ

224.45

+1.24%↑

UNH

385.5

+1.52%↑

TMO

458.32

+0.23%↑

ISRG

427.6

-0.15%↓

ABT

83.46

+0.3%↑

JNJ

224.45

+1.24%↑

UNH

385.5

+1.52%↑

TMO

458.32

+0.23%↑

ISRG

427.6

-0.15%↓

ABT

83.46

+0.3%↑

JNJ

224.45

+1.24%↑

UNH

385.5

+1.52%↑

TMO

458.32

+0.23%↑

ISRG

427.6

-0.15%↓

ABT

83.46

+0.3%↑

JNJ

224.45

+1.24%↑

UNH

385.5

+1.52%↑

TMO

458.32

+0.23%↑

ISRG

427.6

-0.15%↓

ABT

83.46

+0.3%↑

Home・Elenco Azioni・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Aperta

SettoreSettore sanitario

14.49 0.21

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14.49

Massimo

14.49

Metriche Chiave
By Trading Economics
Entrata	-16M 1.7M
Vendite	16M 185M
Margine di Profitto	0.912
Dipendenti	511
EBITDA	-31M 16M

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	61M 4.5B
Apertura precedente	14.28
Chiusura precedente	14.49

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

5.925 / 7.38 Supporto e resistenza

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 23:08 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 23:07 UTC

Utili

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:20 UTC

Utili

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr 2026, 23:27 UTC

Discorsi di Mercato

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr 2026, 23:22 UTC

Utili

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr 2026, 23:20 UTC

Discorsi di Mercato

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr 2026, 22:52 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:33 UTC

Utili

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr 2026, 22:05 UTC

Utili

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 21:57 UTC

Utili

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr 2026, 21:55 UTC

Utili

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr 2026, 21:53 UTC

Utili

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

5.925 / 7.38Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Notizie finanziarie

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.